To assess the translational generalizability of combined ERK and Mediator kinase inhibition, we evaluated this strategy across multiple in vitro and in vivo models of KRAS-mutant cancer, including additional eight-week time-to-progression models, patient-derived rectal cancer tumoroids, and a pancreatic cancer mouse model. Here, KRAS is linked to cancer.